Shots:
Blueprint to receive $535M including $25M up front and up to
$510M as development- regulatory & commercial milestone for BLU-782 in up
to two indications- including FOP with royalties on global sales of BLU-782The collaboration robust Ipsen’s rare diseases portfolio and accelerates
Blueprint’s aim to globally develop BLU-782 by utilizing Ipsen’s clinical
expertise in rare diseases and global infrastructureBlueprint’s BLU-782 is a selective ALK2 inhibitor- being
evaluated in P-I study and has received FDA’s rare pediatric disease
designation- orphan drug designation and fast track designation for the
treatment of FOP
Click here to read full press release/ article | Ref: Ipsen | Image: Genetic Engineering and Biotechnology News
